Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 3
2019 5
2020 6
2021 8
2022 11
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
Souza R, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Lin J, Johnson-Levonas AO, de Oliveira Pena J, Humbert M, Hoeper MM. Souza R, et al. Eur Respir J. 2023 Sep 21;62(3):2301107. doi: 10.1183/13993003.01107-2023. Print 2023 Sep. Eur Respir J. 2023. PMID: 37696565 Free PMC article.
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Park DH, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Lange TJ, Rosenkranz S. Hoeper MM, et al. Eur Respir J. 2022 Jul 7;60(1):2102311. doi: 10.1183/13993003.02311-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 34737226 Free PMC article.
S2k-Leitlinie Hilfsmittelberatung.
Butea-Bocu M, Foller S, Gleisner J, Kahlmeyer A, Karstedt H, Kirschner-Hermanns R, Liebald T, Linne C, Manseck A, Moll V, Otto U, Piotrowski A, Schorn A, Stein J, Wagner A, Wiedemann A; Als Mandatsträger weiterer Fachgesellschaften: Dt. Gesellschaft für Geriatrie: Dr. Klaus Becher; Dt. Gesellschaft für Gynäkologie und Geburtshilfe: Prof. Dr. Christl Reisenauer; Dt. Kontinenz Gesellschaft e. V.: Prof. Dr. Daniela Schultz-Lampel; GKV-Spitzenverband: Dr. Christine Kuhlmann; Dt. Gesellschaft für Pflegewissenschaften: Dr. Daniela Hayder-Beichel; Inkontinenz Selbsthilfe e. V.: Mathias Zeisberger. Butea-Bocu M, et al. Aktuelle Urol. 2021 Apr;52(2):168-180. doi: 10.1055/a-1293-2831. Epub 2021 Apr 1. Aktuelle Urol. 2021. PMID: 33822346 German. No abstract available.
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.
Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Park DH, Ghofrani HA, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Lange TJ, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt KH, Swift AJ, Thompson AAR, Elliot CA, Rosenkranz S, Condliffe R, Kiely DG, Halank M. Hoeper MM, et al. Lancet Respir Med. 2022 Oct;10(10):937-948. doi: 10.1016/S2213-2600(22)00097-2. Epub 2022 Jun 28. Lancet Respir Med. 2022. PMID: 35777416 Free PMC article.
FUNDING: COMPERA is funded by unrestricted grants from Acceleron, Bayer, GlaxoSmithKline, Janssen, and OMT. The ASPIRE Registry is supported by Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK....
FUNDING: COMPERA is funded by unrestricted grants from Acceleron, Bayer, GlaxoSmithKline, Janssen, and OMT. The ASPIRE Registry is su …
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, Rosenkranz S, Vizza CD, Vonk-Noordegraaf A, White RJ, Chang M, Kleinjung F, Meier C, Paraschin K, Ghofrani HA, Simonneau G; REPLACE investigators. Hoeper MM, et al. Lancet Respir Med. 2021 Jun;9(6):573-584. doi: 10.1016/S2213-2600(20)30532-4. Epub 2021 Mar 24. Lancet Respir Med. 2021. PMID: 33773120 Clinical Trial.
INTERPRETATION: Switching to riociguat from PDE5i treatment, both of which act via the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate pathway, could be a strategic option for treatment escalation in patients with PAH at intermediate risk of 1-year mortality …
INTERPRETATION: Switching to riociguat from PDE5i treatment, both of which act via the nitric oxide-soluble guanylate cyclase-cyclic guanosi …
Risk assessment in pulmonary arterial hypertension.
Hoeper MM, Pittrow D, Opitz C, Gibbs JSR, Rosenkranz S, Grünig E, Olsson KM, Huscher D. Hoeper MM, et al. Eur Respir J. 2018 Mar 29;51(3):1702606. doi: 10.1183/13993003.02606-2017. Print 2018 Mar. Eur Respir J. 2018. PMID: 29599117 Free article. No abstract available.
47 results